ZyVersa Therapeutics News

Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it

BenzingaApr 30 01:04

What's Going On With ZyVersa Stock?

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) shares are trading higher Monday after the company announced the publication of a scientific paper in a peer-reviewed journal that reinforces the rationale for

BenzingaApr 29 22:53

ZyVersa Therapeutics Stock Jumps 8%

RTTNewsApr 29 22:19

ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt

ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt

BenzingaApr 29 22:07

ImmunityBio, Aquestive Therapeutics, Clever Leaves Holdings Among Healthcare Movers

Seeking AlphaApr 29 22:02

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC With IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients With Alzheimer's Disease

This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates that multiple inflammasome triggers (NLRP1 and pyrin)

GlobeNewswireApr 29 19:57

Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Aon posted adjusted earnings of $5.66 per share, missing ma

BenzingaApr 27 01:56

PEGY, CGEM and IFBD Among Mid-day Movers

Seeking AlphaApr 27 01:09

ZyVersa Therapeutics To Carry Out 1-for-10 Reverse Stock Split On April 26th, 2024

April 25th - $ZyVersa Therapeutics(ZVSA.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 26th, 2024.$ZyVersa Ther

Futu NewsApr 25 07:40

ZyVersa Therapeutics Approves Reverse Stock Split

TipRanksApr 18 04:42

ZyVersa Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

ZyVersa Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow JonesMar 26 18:27

Buy Rating Affirmed: ZyVersa Therapeutics' Promising Pipeline and Strategic Advancements

TipRanksMar 26 18:17

HC Wainwright & Co. Reiterates Buy on ZyVersa Therapeutics, Maintains $12 Price Target

HC Wainwright & Co. analyst Ed Arce reiterates ZyVersa Therapeutics with a Buy and maintains $12 price target.

Analyst UpgradesMar 26 18:16

Zyversa Therapeutics' 1-for-35 Reverse Split: Navigating the Risks to Shareholder Value and Liquidity

TipRanksMar 26 14:00

ZyVersa Therapeutics GAAP EPS of -$0.29

Seeking AlphaMar 26 04:07

ZyVersa Therapeutics FY23 EPS $(108.97)

ZyVersa Therapeutics FY23 EPS $(108.97)

BenzingaMar 25 20:26

Press Release: ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update Key Highlights: -- Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical tria

Dow JonesMar 25 20:17

ZyVersa Gets IRB Nod for Kidney Drug Phase 2a Trial

ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA), a biopharmaceutical company, has received Institutional Review Board (IRB) approval to proceed with a Phase 2a clinical trial for its Cholesterol Efflux Mediator VAR 200, a drug under development for the treatment of diabetic kidney disease.

Investing.com Mar 18 20:08

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients With Diabetic Kidney Disease

Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to chronic

GlobeNewswireMar 18 19:57

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled "Inflammation Illuminated,"at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024

According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.ZyVersa is developing Inflammasome ASC

GlobeNewswireMar 14 19:57